Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Commentary on: Testosterone replacement therapy and cardiovascular disease

A Correction to this article was published on 14 November 2022

This article has been updated

In this review, previous studies have demonstrated that TRT may be associated with decreased rates of adverse cardiovascular events with lower morbidties and mortality. Crucial outcomes of future randomized trials such as the TRAVERSE STUDY—Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men is eagerly awaited to shed some light on the safety and potential impact of TRT use on cardiovascular health and risks. Until then, it is recommended that clinicians carefully monitor potential cardiac side effects of patients using TRT.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Change history

References

  1. Mulhall JP, Trost LW, Brannigan RE, Kurtz EG, Redmon JB, Chiles KA, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200:423–32.

    Article  PubMed  Google Scholar 

  2. Morgentaler A, Miner MM, Caliber M, Guay AT, Khera M, Traish AM. Testosterone therapy and cardiovascular risk: advances and controversies. Mayo Clin Proc. 2015. https://doi.org/10.1016/j.mayocp.2014.10.011.

  3. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010. https://doi.org/10.1056/NEJMoa1000485.

  4. Auerbach JM, Khera M. Testosterone replacement therapy and cardiovascular disease. Int J Impot Res. 2022. https://doi.org/10.1038/s41443-021-00516-6.

  5. Etminan M, Skeldon SC, Goldenberg SL, Carleton B, Brophy JM. Testosterone therapy and risk of myocardial infarction: a pharmacoepidemiologic study. Pharmacotherapy. 2015. https://doi.org/10.1002/phar.1534.

  6. Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS, Jones TH. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab. 2004. https://doi.org/10.1210/jc.2003-031069.

  7. Kelly DM, Jones TH. Testosterone and obesity. Obes Rev. 2015. https://doi.org/10.1111/obr.12282.

  8. Haddad RM, Kennedy CC, Caples SM, Tracz MJ, Boloña ER, Sideras K, et al. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007. https://doi.org/10.4065/82.1.29.

  9. Nackeeran S, Kohn T, Gonzalez D, White J, Ory J, Ramasamy R. The effect of route of testosterone on changes in hematocrit: a systematic review and bayesian network meta-analysis of randomized trials. J Urol. 2022;207:44–51.

    Article  PubMed  Google Scholar 

  10. A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men (TRAVERSE). ClinicalTrials.gov. ClinicalTrials.gov Identifier: NCT03518034.

Download references

Author information

Authors and Affiliations

Authors

Contributions

All authors contributed equally to paper. Authors DN and DS contributed to analyzing data and writing papers and references. Author OAR contributed and supervised the complete and final version of the paper and provided extensive revisions and final conclusions.

Corresponding author

Correspondence to Omer A. Raheem.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original online version of this article was revised: In this article the title was incorrectly given as “Commentary on: Testosterone replacement therapy and cardiovascular disease IJIR-11-2021-317” but should have been “Commentary on: Testosterone replacement therapy and cardiovascular disease”. The original article has been corrected.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Nusbaum, D., Sudhakar, D. & Raheem, O.A. Commentary on: Testosterone replacement therapy and cardiovascular disease. Int J Impot Res 34, 691–692 (2022). https://doi.org/10.1038/s41443-022-00625-w

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41443-022-00625-w

Search

Quick links